JP6885671B2 - 化学毒性および年齢関連性の病気から保護するための方法および食事制限 - Google Patents

化学毒性および年齢関連性の病気から保護するための方法および食事制限 Download PDF

Info

Publication number
JP6885671B2
JP6885671B2 JP2015557219A JP2015557219A JP6885671B2 JP 6885671 B2 JP6885671 B2 JP 6885671B2 JP 2015557219 A JP2015557219 A JP 2015557219A JP 2015557219 A JP2015557219 A JP 2015557219A JP 6885671 B2 JP6885671 B2 JP 6885671B2
Authority
JP
Japan
Prior art keywords
protein
diet
low
calories
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015557219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509994A5 (https=
JP2016509994A (ja
Inventor
ディー． ロンゴ，ヴァルトル
ディー． ロンゴ，ヴァルトル
ブランドホルスト，セバスチャン
エリース レヴィン，モーガン
エリース レヴィン，モーガン
Original Assignee
ユニバーシティ オブ サザン カリフォルニア
ユニバーシティ オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ サザン カリフォルニア, ユニバーシティ オブ サザン カリフォルニア filed Critical ユニバーシティ オブ サザン カリフォルニア
Publication of JP2016509994A publication Critical patent/JP2016509994A/ja
Publication of JP2016509994A5 publication Critical patent/JP2016509994A5/ja
Application granted granted Critical
Publication of JP6885671B2 publication Critical patent/JP6885671B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
JP2015557219A 2013-02-12 2014-02-12 化学毒性および年齢関連性の病気から保護するための方法および食事制限 Active JP6885671B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
US61/763,797 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019179570A Division JP2020073473A (ja) 2013-02-12 2019-09-30 化学毒性および年齢関連性の病気から保護するための方法および食事制限

Publications (3)

Publication Number Publication Date
JP2016509994A JP2016509994A (ja) 2016-04-04
JP2016509994A5 JP2016509994A5 (https=) 2017-03-09
JP6885671B2 true JP6885671B2 (ja) 2021-06-16

Family

ID=51297596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557219A Active JP6885671B2 (ja) 2013-02-12 2014-02-12 化学毒性および年齢関連性の病気から保護するための方法および食事制限
JP2019179570A Pending JP2020073473A (ja) 2013-02-12 2019-09-30 化学毒性および年齢関連性の病気から保護するための方法および食事制限

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019179570A Pending JP2020073473A (ja) 2013-02-12 2019-09-30 化学毒性および年齢関連性の病気から保護するための方法および食事制限

Country Status (12)

Country Link
US (3) US9237761B2 (https=)
EP (2) EP2956776A4 (https=)
JP (2) JP6885671B2 (https=)
KR (1) KR20150124962A (https=)
CN (3) CN114236130A (https=)
AU (3) AU2014216349B2 (https=)
BR (1) BR112015019223A2 (https=)
CA (1) CA2900782C (https=)
ES (1) ES2807781T3 (https=)
MX (1) MX382484B (https=)
RU (2) RU2018141475A (https=)
WO (1) WO2014127000A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3125904A4 (en) 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
AU2016219173B2 (en) 2015-02-12 2020-02-20 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
KR20180002677A (ko) * 2015-04-16 2018-01-08 유니버시티 오브 써던 캘리포니아 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물
BR112017023748A2 (pt) * 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) * 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
AU2019280170B2 (en) * 2018-06-07 2024-03-28 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
WO2020015842A1 (en) 2018-07-18 2020-01-23 Michalsen Andreas Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
US20200147112A1 (en) * 2018-10-04 2020-05-14 Meiji Co., Ltd. Diet therapy of intractable cancer and medical diet suitable therefor
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
CA3134756A1 (en) * 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
IT202000008740A1 (it) 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
CN116096251A (zh) * 2020-09-23 2023-05-09 氨基维他有限公司 癌症的代谢疗法
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
TW202541716A (zh) * 2023-12-14 2025-11-01 美商艾爾 紐特拉公司 用於延長壽命、增強體力和機能的可食用產品及其食用和製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
AU2002320100A1 (en) * 2001-06-15 2003-01-02 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007088046A2 (en) * 2006-02-01 2007-08-09 Nestec S.A. Nutritional system and methods for increasing longevity
ES2800327T3 (es) * 2008-04-24 2020-12-29 Univ Of Southern California Usc Stevens Composiciones dietéticas y métodos de protección contra la quimioterapia o radioterapia
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装

Also Published As

Publication number Publication date
KR20150124962A (ko) 2015-11-06
AU2020200297A1 (en) 2020-02-06
HK1212028A1 (en) 2016-06-03
CN109187991A (zh) 2019-01-11
RU2018141475A3 (https=) 2022-03-29
RU2015134780A (ru) 2017-03-20
AU2014216349A1 (en) 2015-08-06
US9237761B2 (en) 2016-01-19
US20160331016A1 (en) 2016-11-17
RU2674681C2 (ru) 2018-12-12
BR112015019223A2 (pt) 2017-07-18
ES2807781T3 (es) 2021-02-24
US20140227373A1 (en) 2014-08-14
CN105008929B (zh) 2018-10-02
CA2900782C (en) 2022-09-27
EP2956776A4 (en) 2016-12-21
EP3510875B1 (en) 2020-06-10
WO2014127000A2 (en) 2014-08-21
AU2014216349B2 (en) 2019-10-24
AU2020200297B2 (en) 2022-04-07
CN114236130A (zh) 2022-03-25
AU2022202764A1 (en) 2022-05-19
US20170035094A1 (en) 2017-02-09
CA2900782A1 (en) 2014-08-21
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
JP2020073473A (ja) 2020-05-14
EP2956776A2 (en) 2015-12-23
EP3510875A1 (en) 2019-07-17
MX382484B (es) 2025-03-13
JP2016509994A (ja) 2016-04-04
CN109187991B (zh) 2021-12-24
CN105008929A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
JP6885671B2 (ja) 化学毒性および年齢関連性の病気から保護するための方法および食事制限
Murphy et al. Dietary protein to maintain muscle mass in aging: a case for per-meal protein recommendations
RU2672594C2 (ru) Состояние воздержания от пищи в качестве диетического лечения диабета
CN116114873A (zh) 禁食模仿膳食包的用途
Bouillanne et al. Long-lasting improved amino acid bioavailability associated with protein pulse feeding in hospitalized elderly patients: A randomized controlled trial
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
de Lorgeril et al. The Mediterranean diet in secondary prevention of coronary heart disease
US20160008309A1 (en) Use of trans-palmitoleate in identifying and treating metabolic disease
Ogura et al. Effects of ostrich meat intake on amino acid metabolism and growth hormone secretion: A comparative clinical study.
Andreevski et al. Pulmonary cachexia-a review of malnutrition in patients with advanced lung diseases and strategies for diet therapy.
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
HK40002950A (en) Method for providing reasonable protein diet to subject
Pal et al. An exquisite analysis on the significance of nutrient supplementation in the holistic management of poly-cystic ovarian syndrome
US12285453B2 (en) Fasting-mimicking diet promotes cancer-free survival in acute lymphoblastic leukemia models
HK1212028B (en) Methods and diets to protect against chemotoxicity and age related illnesses
US20220175007A1 (en) Fasting mimicking ketogenic diet to improve immune function and vaccine response and minimize risk in adults and elderly
EP4565324A1 (en) Vitamin a-free nutritional compositions for treating dysfunction of liver fat metabolism
Wong Nutritional characteristics of breast milk in Hong Kong lactating women

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190528

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200512

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200901

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200901

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210323

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210420

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210513

R150 Certificate of patent or registration of utility model

Ref document number: 6885671

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250